Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Gina M Mantia-Smaldone1, Robert P Edwards2, Anda M Vlad31Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 2Division of Gynecologic Oncology, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 3Department of O...

Detaylı Bibliyografya
Asıl Yazarlar:	Gina M Mantia-Smaldone, Robert P Edwards, Anda M Vlad
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	Dove Medical Press 2010-12-01
Seri Bilgileri:	Cancer Management and Research
Online Erişim:	http://www.dovepress.com/targeted-treatment-of-recurrent-platinum-resistant-ovarian-cancer-curr-a5977

Benzer Materyaller

799 Combination intraperitoneal chemoimmunotherapy triggers a T-cell chemotactic locoregional response in patients with recurrent platinum-sensitive ovarian cancer
Yazar:: Lixin Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
Yazar:: K. E. Borisov
Baskı/Yayın Bilgisi: (2014-07-01)

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer
Yazar:: Woraporn Sinsuwan, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer
Yazar:: Shushant Chib, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Progress of Surgery on Platinum-sensitive Recurrent Ovarian Cancer
Yazar:: HE Liya, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Yazar:: Ruoyao Zou, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
Yazar:: Zhongmian Pan, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype
Yazar:: Sean Cronin, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Yazar:: Eduardo Gonzalez-Ochoa, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer
Yazar:: Hiroaki Ishida, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment
Yazar:: Jeremy eChien, ve diğerleri
Baskı/Yayın Bilgisi: (2013-09-01)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
Yazar:: Eva María Guerra Alía, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies
Yazar:: K Veskimäe, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report
Yazar:: Yong Wu, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)

Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Yazar:: Xin Cui, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Yazar:: Eric A Benson, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
Yazar:: Roberta Affatato, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
Yazar:: Ramez N. Eskander, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
Yazar:: Andrei Havasi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
Yazar:: Kaname Uno, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer
Yazar:: Nina Oufkir, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data
Yazar:: Li-Rong Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
Yazar:: Qian Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer
Yazar:: Yinan Jiang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer
Yazar:: Ying Yan MD, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Yazar:: Diogo Torres, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
Yazar:: Yin-Ting Chuang, ve diğerleri
Baskı/Yayın Bilgisi: (2012-09-01)

The function of TTK1 in platinum-resistant ovarian cancer
Yazar:: LIU Yixuan , WEN Zexuan , GUO Lin , LU Renquan
Baskı/Yayın Bilgisi: (2021-03-01)

IS HIPEC BENEFICIAL IN PLATINUM RESISTANT RELAPSED OVARIAN CANCER?
Yazar:: Nicolae Bacalbasa, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Platinum resistance in breast and ovarian cancer cell lines
Yazar:: Eckstein Niels
Baskı/Yayın Bilgisi: (2011-10-01)

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
Yazar:: I. A. Pokataev, ve diğerleri
Baskı/Yayın Bilgisi: (2015-11-01)

Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study
Yazar:: Laurence Morin, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer
Yazar:: Petronella O. Witteveen, ve diğerleri
Baskı/Yayın Bilgisi: (2010-11-01)

Multi-line Treatment Combined Apatinib with Toptecan for Platinum-resistant Recurrent Ovarian Cancer: Two Cases Report
Yazar:: CHENG Yuan, ve diğerleri
Baskı/Yayın Bilgisi: (2018-03-01)

Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer
Yazar:: C. Lan, ve diğerleri
Baskı/Yayın Bilgisi: (2019-02-01)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
Yazar:: Ram N. Ganapathi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Puerarin induces platinum-resistant epithelial ovarian cancer cell apoptosis by targeting SIRT1
Yazar:: Jianxiu Duan, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
Yazar:: Aditi Bhatt, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
Yazar:: Francesca Ricci, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer
Yazar:: Ni J, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)